Cefozopran
Chemical compound
- J01DE03 (WHO)
- (6R,7R)-7-[[(2Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)- 2-methoxyiminoacetyl]amino]-3-(imidazo[2,3-f]pyridazin- 4-ium-1-ylmethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0] oct-2-ene-2-carboxylate
- 113359-04-9 Y
- 9571080
- 7845546 N
- 1LG87K28LW
- D01052 Y
- ChEMBL1276663 N
- Interactive image
- O=C2N1/C(=C(\CS[C@@H]1[C@@H]2NC(=O)C(=N\OC)/c3nc(sn3)N)Cn5c4cccn[n+]4cc5)C([O-])=O
InChI
- InChI=1S/C19H17N9O5S2/c1-33-24-11(14-23-19(20)35-25-14)15(29)22-12-16(30)28-13(18(31)32)9(8-34-17(12)28)7-26-5-6-27-10(26)3-2-4-21-27/h2-6,12,17H,7-8H2,1H3,(H3-,20,22,23,25,29,31,32)/b24-11-/t12-,17-/m1/s1 N
- Key:QDUIJCOKQCCXQY-WHJQOFBOSA-N N
Cefozopran (INN) is a fourth-generation cephalosporin.[1]
Spectrum of bacterial susceptibility and resistance
Most of the strains of Stenotrophomonas maltophilia have developed resistance toward cefozopran.[2]
References
- v
- t
- e
(inhibit synthesis
of peptidoglycan
layer of bacterial
cell wall by binding
to and inhibiting
PBPs, a group of
D-alanyl-D-alanine
transpeptidases)
Glycopeptides Lipoglycopeptides |
|
---|---|
Lipopeptides |
|
Polymyxins |
|
Other |
|
- Inhibit PG subunit synthesis and transport: NAM synthesis inhibition (Fosfomycin)
- DADAL/AR inhibitors (Cycloserine)
- bactoprenol inhibitors (Bacitracin)
- Hydrolyze NAM-NAG
- Tyrothricin
- Isoniazid#
- Teixobactin
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
This systemic antibiotic-related article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e